Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

NCT01751308 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumor - Malignant Nervous System Neoplasm

Interventions

DRUG: Cabazitaxel (XRP6258)

Sponsor

Sanofi